5th AAVP Forum: RV144 proves an HIV vaccine is possible

Submitted by tusabe about 9 months ago

In September, 2009, researchers in the Thailand trialannounced that a combination regimen reduced HIV risk by approximately 30% in volunteers who received any or all of the course of six immunizations.

Additional data released in October 2009, showed the same pattern of fewer infections in vaccine recipients compared to placebo recipients.

The Thailand prime-boost trial, also known as RV144, began in 2003 and enrolled more than 16,400 HIV negative Thai men and women between ages of 18 and 30.

It was conducted by the Thai government of Health. The trial tested a combination of two vaccines: ALVAC HIV vaccine (the prime) and AIDSVAX B/E vaccine (the Boost) and was designed to evaluate whether this vaccine regimen reduced risk of HIV infection and or whether participants who received the vaccine and went on to acquire HIV had lower viral loads than participants who received the placebo and acquired HIV.

On 24th September, 2009, results showed that the regimen lowered the rate of HIV infection by 31.2% compared to the placebo.

The findings highlighted that the vaccine had no effect on the viral load. The trial duration was from 2003 to 2009 with a total of 16,402 participants.

It was noted that only 74 out of 8,198 volunteers who received placebo immunization became infected with HIV compared to 51 out of 8,197 volunteers who received the vaccine regimen of ALVACvCP1521 and AIDSVAX B/E.

Detailed Data can be found in the new England Journal of medicine http://content.nejm.org/ and more information about the findings via www.avac.org/thaitrial.htm.

Keywords: 5TH AAVP CONFERENCE HIV VACCINE TRIAL RESEARCH HIV/AIDS Thailand Uganda

Uganda 0 comments Mail a friend Edit